StockData
Lifecore Biomedical, Inc. logo

Lifecore Biomedical, Inc. (LFCR) stock

LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
Financials through Q3 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30
$6.42+0.02 (+0.31%)

Close on Nov 13, 2026Market cap $243.02MP/E –Yield –

Earnings

Lifecore Biomedical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2027
$25.30M
Adjusted EPS, Q3 FY2027
-$1.08
Latest guidance
Issued
Aug 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Lifecore Biomedical's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2027ended Sep 30, 2026Nov 4, 2026before the open$25.30M–-$1.08–Release
Q2 FY2027ended Jun 30, 2026Aug 5, 2026before the open$34.20M–-$0.19–Release
Q1 FY2026ended Sep 30, 2025Nov 6, 2025during market hours$31.10M+25.9%-$0.29–Release
Q4 FY2025ended May 25, 2025Aug 7, 2025during market hours$36.40M-4.0%-$0.06–Release
Q3 FY2025ended Feb 23, 2025Apr 3, 2025during market hours$35.20M–––Release
Q2 FY2025ended Nov 24, 2024Jan 2, 2025during market hours$32.60M–––Release
Q1 FY2025ended Aug 25, 2024Oct 4, 2024before the open$24.70M-21.6%-$0.53–Release
Q4 FY2024ended May 26, 2024Aug 26, 2024during market hours$37.90M+37.3%––Release
Q3 FY2024ended Feb 25, 2024Mar 20, 2024before the open––––Release
Q1 FY2024ended Aug 27, 2023Aug 31, 2023before the open$31.50M-27.4%-$1.11-$0.89Release
Q4 FY2023ended May 28, 2023Jun 1, 2023before the open$27.60M-42.0%-$0.51-$0.22Release
Q3 FY2023ended Feb 26, 2023Jun 1, 2023before the open$27.60M-48.0%-$0.51-$0.22Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Lifecore Biomedical guided for has been reported

Guidance vs results

The last range Lifecore Biomedical gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$126.50M – $130.00M$128.90MΣ4QWithin range

Guidance history

Every forecast Lifecore Biomedical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026Adjusted EBITDAFY2026$20.50M – $25.00MNew
Aug 5, 2026revenueFY2026$120.00M – $125.00MNew
Nov 6, 2025Adjusted EBITDAFY2025$12.00M – $14.00MLowered
Nov 6, 2025revenueFY2025$74.00M – $76.00MLowered
Aug 7, 2025Adjusted EBITDAFY2025$12.00M – $14.00MLowered
Aug 7, 2025revenue CAGRover the mid-term+12%–
Aug 7, 2025adjusted EBITDA* marginsover the mid-term25%–
Aug 7, 2025revenueFY2025$74.00M – $76.00MNew
Apr 3, 2025Adjusted EBITDAFY2025$19.00M – $21.00MNew
Apr 3, 2025revenueFY2025$126.50M – $130.00MNew
Oct 4, 2024Adjusted EBITDAFY2025$19.00M – $21.00MReaffirmed
Oct 4, 2024revenueFY2025$126.50M – $130.00MReaffirmed
Aug 26, 2024Capital expendituresFY2025$10.00M – $14.00MNew
Aug 26, 2024Adjusted EBITDAFY2025$19.00M – $21.00MNew
Aug 26, 2024RevenueFY2025$126.50M – $130.00MNew
Oct 6, 2022Lifecore segment adjusted EBITDAFY2023$31.00M – $32.50MReaffirmed
Oct 6, 2022Consolidated adjusted EBITDA*FY2023$23.50M – $25.50MLowered
Oct 6, 2022Other segment (corporate expense)FY2023-$7.50M – -$7.00MNew
Oct 6, 2022Lifecore segment revenueFY2023$122.00M – $126.00MReaffirmed
Aug 10, 2022Lifecore segment adjusted EBITDAFY2023$31.00M – $32.50MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Lifecore Biomedical filed with the SEC as exhibits to Form 8-K or 6-K

  1. Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026 , and Provides Corporate Update
    Results
  2. Lifecore Biomedical to be Acquired by Webster Equity Partners
    Update
  3. payments of $3.39 per share, based upon company achievement of performance milestones in 2028-2030 and assuming full performance milestone payments of $160 million in the aggregate . Upon completion
    Update
  4. An Exciting Path Forward September 28, 2026 EXHIBIT 99.3
    Update
  5. Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026 , and Provides Corporate Update
    Results
  6. Building a high-performing, growth-focused, sterile injectable CDMO August 2026 Exhibit 99.2
    Results
  7. Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026 , and Provides Corporate Update
    Results
  8. Building a high-performing, growth-focused, sterile injectable CDMO May 2026
    Results
  9. Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
    Results
  10. Building a high-performing, growth-focused, sterile injectable CDMO March 2026
    Results
  11. Building a high-performing, growth-focused, sterile injectable CDMO Jefferies Global Healthcare Conference November 2025
    Update
  12. Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update
    Results
  13. Executing Three-Pronged Growth Strategy Maximizing Existing Customer Business Advancing Programs Towards Commercialization Driving New Business 10
    Results
  14. Executing Three-Pronged Growth Strategy Maximizing Existing Customer Business Advancing Programs Towards Commercialization Driving New Business 10
    Update
  15. Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
    Results

See a number that looks wrong?